BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 30 minutes later, on .
Signal breakdown
CurrentWire ranked this story 60.5 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.5 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 5.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 33.5 of 35. How each signal is calculated.
Filed under General · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Survival Data Reinforcing Benefit (none), ZIIHERA-Containing Regimens (none), Gastroesophageal Cancer (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.